Diversify Wealth Management LLC Makes New $998,000 Investment in Ascendis Pharma A/S (NASDAQ:ASND)

Diversify Wealth Management LLC bought a new stake in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 5,994 shares of the biotechnology company's stock, valued at approximately $998,000.

Several other large investors have also recently bought and sold shares of the stock. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Ascendis Pharma A/S in the fourth quarter worth about $28,000. Jones Financial Companies Lllp boosted its holdings in shares of Ascendis Pharma A/S by 394.0% in the fourth quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company's stock worth $34,000 after buying an additional 197 shares during the period. Quarry LP acquired a new position in shares of Ascendis Pharma A/S in the fourth quarter worth about $96,000. Tower Research Capital LLC TRC boosted its holdings in shares of Ascendis Pharma A/S by 195.3% in the fourth quarter. Tower Research Capital LLC TRC now owns 1,004 shares of the biotechnology company's stock worth $138,000 after buying an additional 664 shares during the period. Finally, GF Fund Management CO. LTD. acquired a new position in shares of Ascendis Pharma A/S in the fourth quarter worth about $174,000.

Ascendis Pharma A/S Stock Performance

NASDAQ ASND traded up $0.65 during trading hours on Wednesday, reaching $175.40. 426,384 shares of the company's stock were exchanged, compared to its average volume of 505,054. The company's 50-day moving average is $168.60 and its two-hundred day moving average is $154.01. Ascendis Pharma A/S has a one year low of $111.09 and a one year high of $183.00. The company has a market capitalization of $10.72 billion, a price-to-earnings ratio of -27.93 and a beta of 0.38.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The biotechnology company reported ($1.66) earnings per share for the quarter, missing analysts' consensus estimates of ($1.56) by ($0.10). The business had revenue of $123.97 million during the quarter, compared to analysts' expectations of $98.56 million. Research analysts predict that Ascendis Pharma A/S will post -4.34 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts recently commented on ASND shares. Bank of America raised their price target on shares of Ascendis Pharma A/S from $201.00 to $216.00 and gave the stock a "buy" rating in a report on Monday, June 9th. Oppenheimer restated an "outperform" rating and set a $224.00 price target (up from $215.00) on shares of Ascendis Pharma A/S in a report on Friday, June 13th. Citigroup raised their price objective on shares of Ascendis Pharma A/S from $213.00 to $243.00 and gave the company a "buy" rating in a research report on Friday, July 11th. Wedbush raised their price objective on shares of Ascendis Pharma A/S from $181.00 to $212.00 and gave the company an "outperform" rating in a research report on Friday, May 2nd. Finally, Evercore ISI raised their price objective on shares of Ascendis Pharma A/S from $260.00 to $280.00 and gave the company an "outperform" rating in a research report on Friday, May 2nd. One analyst has rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $223.07.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.